A recent FDA investigation of Invokana and other SGLT2 inhibitors discovered that this class of type II diabetes drug may cause ketoacidosis and resulting complications such as kidney failure, heart attack, stroke, cardiovascular complications, diabetic coma and even death. Recently there have been numerous adverse event reports submitted to the FDA by physicians and patients following the prescription and use of sodium-glucose cotransporter-2s.
This class of drugs/medications known as SGLT2 inhibitors were designed to cause the release of excess blood sugars into the urine. Invokana and the other SGLT2 inhibitors are intended to improve glycemic control in adults with type II diabetes by lowering a user’s blood sugar by causing the kidneys to remove the sugar through one's urine. However, use of these pharmaceutical products has been found to increase the risk of ketoacidosis, which develops when the body is unable to produce sufficient insulin. Without sufficient insulin adequate quantities of glucose may not get to one's cells and muscles leading to a toxic acid buildup in the patient's bloodstream. A type II diabetes patient developing ketoacidosis may experience dizziness, difficulty breathing, hyperventilation, lack of energy and unusual fatigue/lethargy.
If you or a loved one was prescribed Invokana or another sodium-glucose cotransporter-2 and suffered serious side effects or injuries following its use, you may be entitled to legal compensation. Our firm has been involved in numerous prior pharmaceutical mass tort cases on behalf of persons experiencing catastrophic injuries after taking prescription drugs where the pharmaceutical manufacturer failed to disclose all the risks associated with their product/drug. Jack Meyerson
and Debora O’Neill
will be coordinating our firm’s handling of all cases arising from the use of SGLT2 drugs. To learn more about your legal rights please contact one of our experienced pharmaceutical attorneys
or submit a claim form
for a free and confidential consultation.